HIGH-ACTIVITY I-125 INTERSTITIAL IRRADIATION IN THE TREATMENT OF PEDIATRIC CENTRAL-NERVOUS-SYSTEM TUMORS - A PILOT-STUDY

被引:4
|
作者
FONTANESI, J
HEIDEMAN, RL
MUHLBAUER, M
MULHERN, R
SANFORD, RA
DOUGLASS, EC
KOVNAR, E
OCHS, JJ
KUTTESCH, JF
TAI, D
KUN, LE
机构
[1] ST JUDE CHILDRENS RES HOSP, DEPT RADIAT ONCOL, MEMPHIS, TN 38105 USA
[2] ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA
[3] ST JUDE CHILDRENS RES HOSP, DEPT NEUROL, MEMPHIS, TN 38105 USA
[4] ST JUDE CHILDRENS RES HOSP, DIV BEHAV MED, MEMPHIS, TN 38105 USA
[5] UNIV TENNESSEE, COLL MED, DEPT RADIOL, MEMPHIS, TN USA
[6] UNIV TENNESSEE, COLL MED, DEPT NEUROSURG, MEMPHIS, TN USA
[7] UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN USA
[8] ST CHRISTOPHERS HOSP CHILDREN, PHILADELPHIA, PA 19133 USA
关键词
I-125; BRAIN TUMORS; INTERSTITIAL IMPLANTS; PEDIATRIC TUMORS;
D O I
10.1159/000120918
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Malignant pediatric tumors of the central nervous system (CNS) have a poor prognosis, with local failure rates as high as 50%, In an attempt to improve local tumor control, we used stereotactic interstitial therapy with I-125 implants in patients with recurrent/secondary or newly diagnosed CNS malignancies, Catheters were placed using computed tomography (CT) guidance; computerized dosimetry was completed with the aid of orthogonal films. Implants delivered 1,000 cGy/day to the tumor periphery (0.5 cm beyond the boundary of enhancement on CT scans), to a total dose of 60 Gy, Hyperfractionated external beam irradiation (HEBI), started 2-4 weeks after removal of implants, delivered total doses of 66-70.4 Gy in 110-cGy fractions twice daily to a 3-cm margin around the implant volume, Eight of the 1 1 patients with newly diagnosed tumors also received 48.4 Gy HEBI to the craniospinal axis. Tumor regression was noted at 2 months after implantation in the 4 patients treated for recurrent/secondary tumors; local progression was subsequently documented in 2 cases at 6 and 20 months after implantation, while a third patient died 6 months after implantation with no evidence of local recurrence. The remaining recurrent/secondary tumor patient has no evidence of active recurrence 15 months after implantation. Local control was maintained in 9 of the 1 1 patients treated for primary tumors for a median of 27 months (range 15 to 48+ months). The two local failures occurred at 5 and 7 months after implantation. Six patients are alive without evidence of progressive disease (median = 23 months after implantation), There were no severe acute toxicities, but 7 patients later developed histologically confirmed tumor necrosis, Quality of life assessment (QLA) following initial primary therapy with implantation was evaluated utilizing an established criteria and found to be excellent with only one child showing marked QLA score decrease which was related to neurosurgical intervention for radiation-induced necrosis and dysfunctional family social situation, This small series suggests that stereotactic I-125 implantation followed by HEBI merits further evaluation in selected children with supratentorial malignant lesions.
引用
收藏
页码:289 / 297
页数:9
相关论文
共 50 条
  • [21] PREIRRADIATION CISPLATIN AND ETOPOSIDE IN THE TREATMENT OF HIGH-RISK MEDULLOBLASTOMA AND OTHER MALIGNANT EMBRYONAL TUMORS OF THE CENTRAL-NERVOUS-SYSTEM - A PHASE-II STUDY
    KOVNAR, EH
    KELLIE, SJ
    HOROWITZ, ME
    SANFORD, RA
    LANGSTON, JW
    MULHERN, RK
    JENKINS, JJ
    DOUGLASS, EC
    ETCUBANAS, EE
    FAIRCLOUGH, DL
    KUN, LE
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (02) : 330 - 336
  • [22] RESPONSE OF RAT-BRAIN TISSUE FOR THE EXTRACTION OF I-125 ANTIPYRINE AFTER SINGLE AND FRACTIONATED ROENTGEN RAY DOSES - A COMPARISON OF FRACTIONATION MODELS APPLIED TO THE CENTRAL-NERVOUS-SYSTEM
    PITKANEN, MA
    HOPEWELL, JW
    ACTA RADIOLOGICA ONCOLOGY, 1985, 24 (05): : 445 - 450
  • [23] DRUG-INDUCED REGULATION OF [I-125] IODOCYANOPINDOLOL-LABELED 5-HYDROXYTRYPTAMINE(1B) RECEPTOR-BINDING SITES IN THE CENTRAL-NERVOUS-SYSTEM
    PRANZATELLI, MR
    RAZI, P
    NEUROPSYCHOPHARMACOLOGY, 1994, 10 (04) : 259 - 264
  • [24] I-125 BH[SAR9,MET(O2)11]-SP, A NEW SELECTIVE LIGAND FOR THE NK-1 RECEPTOR IN THE CENTRAL-NERVOUS-SYSTEM
    TOUSIGNANT, C
    GUILLEMETTE, G
    DRAPEAU, G
    TELEMAQUE, S
    DION, S
    REGOLI, D
    BRAIN RESEARCH, 1990, 524 (02) : 263 - 270
  • [25] A quantitative autoradiographical study on the distribution of somatostatin sst(2) receptors in the rat central nervous system using [I-125]-BIM-23027
    Holloway, S
    Feniuk, W
    Kidd, EJ
    Humphrey, PPA
    NEUROPHARMACOLOGY, 1996, 35 (08) : 1109 - 1120
  • [26] Topotecan for the Treatment of Recurrent or Progressive Central Nervous System Tumors – A Pediatric Oncology Group Phase II Study
    Richard P. Kadota
    Clinton F. Stewart
    Marianna Horn
    John F. Kuttesch
    Peter C. Burger
    James L. Kepner
    Larry E. Kun
    Henry S. Friedman
    Richard L. Heideman
    Journal of Neuro-Oncology, 1999, 43 : 43 - 47
  • [27] Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study
    Kadota, RP
    Stewart, CF
    Horn, M
    Kuttesch, JF
    Burger, PC
    Kepner, JL
    Kun, LE
    Friedman, HS
    Heideman, RL
    JOURNAL OF NEURO-ONCOLOGY, 1999, 43 (01) : 43 - 47
  • [28] GAMMA KNIFE RADIOSURGERY AS AN EFFICACIOUS TREATMENT FOR PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS: A RETROSPECTIVE STUDY OF 61 NEOPLASMS
    Pahwa, Bhavya
    Agrawal, Deepak
    NEURO-ONCOLOGY, 2022, 24 : 162 - 162
  • [29] STUDY OF FUNCTIONAL-ACTIVITY OF CENTRAL-NERVOUS-SYSTEM AT EARLY POSTRADIATION PERIOD AFTER IRRADIATION WITH DIFFERENT DOSES OF GAMMA-QUANTS
    SAVCHENKO, NY
    IZVESTIYA AKADEMII NAUK SSSR SERIYA BIOLOGICHESKAYA, 1991, (01): : 145 - 147
  • [30] A pilot feasibility study of the use of oxaliplatin (NSC266046) in pediatric patients with refractory or recurrent tumors involving the central nervous system
    Gore, L.
    Maloney, K. W.
    Smith, A. A.
    Foreman, N. K.
    NEURO-ONCOLOGY, 2007, 9 (02) : 207 - 207